Meitheal secures exclusive commercial rights to Xenleta in US
Xenleta is a semi-synthetic pleuromutilin antibiotic originally discovered and developed by Ireland-based Nabriva Therapeutics, as a monotherapy for the treatment of community-acquired bacterial pneumonia (CABP)
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry